Bibliographic Details
| Title: |
A diagnostic model for non-invasive urothelial cancer early detection based on methylation of urinary tumor DNA. |
| Authors: |
Wu, Ningning1 (AUTHOR), Wu, Zhen1 (AUTHOR), Wang, Yanwen2 (AUTHOR), Zhang, Anqi3 (AUTHOR), Peng, Yongfei1 (AUTHOR), Cheng, Yan3 (AUTHOR), Lei, Hongsong4 (AUTHOR), Liu, Siwen1 (AUTHOR), Zhao, Jie1 (AUTHOR) zhao.jie@biochainbj.com, Li, Tianbao1 (AUTHOR) li.tianbao@biochainbj.com, Zhou, Guangpeng1 (AUTHOR) zhou.guangpeng@biochainbj.com |
| Source: |
Cancer Cell International. 4/15/2025, Vol. 25 Issue 1, p1-13. 13p. |
| Subject Terms: |
*WHOLE genome sequencing, *TRANSITIONAL cell carcinoma, *MEDICAL technology, *URINARY organs, *EARLY detection of cancer |
| Abstract: |
Background: Diagnostic methods for urothelial cancer (UC) are often invasive, while urinary cytology, a non-invasive alternative, suffers from limited sensitivity. This study aimed to identify differentially methylated markers in urinary tumor DNA and develop a diagnostic method to enhance the sensitivity of non-invasive UC detection. Methods: Whole-genome bisulfite sequencing and deep methylation sequencing were employed to identify significantly hypermethylated UC-associated genes in clinical samples and public UC datasets. Further screening was conducted using tumor biopsies and urine samples from patients, leading to the selection of three hypermethylated UC markers. A diagnostic model based on these markers was constructed and validated in a cohort (N = 432) comprising patients with UC, other cancers, benign lesions, and non-UC urinary tract diseases. Results: Validation in a cohort of 432 subjects demonstrated that the UC diagnostic model, incorporating three hypermethylated markers (VIM, TMEM220, and PPM1N), achieved an overall sensitivity of 94.44% in 108 UC patients. Specificities were 96.34%, 90.76%, and 87.72% in 191 non-neoplastic individuals, 76 patients with benign lesions, and 57 patients with other cancers, respectively, resulting in an overall specificity of 93.52%. Methylation level analysis revealed significantly higher methylation (P < 0.001) for three markers in UC samples compared to non-UC samples. Furthermore, the model exhibited sensitivities of 80% and 88.57% for detecting stage 0a/0is and stage I UC, respectively. Conclusions: The UC diagnostic model demonstrates excellent diagnostic performance, particularly in the early detection of UC. This non-invasive approach, characterized by high sensitivity and specificity, holds significant potential for further clinical evaluation and development as a reliable tool for UC diagnosis using urine samples. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancer Cell International is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
